Stass H, Kubitza D
Institute of Clinical Pharmacology, Bayer AG, Building 470, D-42096 Wuppertal, Germany.
Clin Infect Dis. 2001 Mar 15;32 Suppl 1:S47-50. doi: 10.1086/319376.
We report a brief description of the interaction profile of moxifloxacin. After oral administration, the absorption of moxifloxacin was unaffected by ranitidine or by food consumption. Drugs containing multivalent cations (e.g., Mg(++), Al(+++), and Fe(++), but not Ca(++)) impaired absorption. No clinically relevant effect of moxifloxacin was seen on the pharmacokinetics of digoxin under combination steady state conditions. Also, moxifloxacin did not affect the pharmacokinetics of theophylline or vice versa. This result, plus further data proving lack of interaction with glyburide, warfarin, and oral contraceptives, confirms the absence of metabolic interactions involving the cytochrome P-450 system, as previously reported. Concomitant administration of probenecid did not affect the elimination of moxifloxacin. Moxifloxacin thus has a unique drug interaction profile that is advantageous for its safe use.
我们报告了莫西沙星相互作用概况的简要描述。口服给药后，雷尼替丁或食物摄入对莫西沙星的吸收没有影响。含有多价阳离子的药物（如Mg(++)、Al(+++)和Fe(++)，但不包括Ca(++)）会损害吸收。在联合稳态条件下，未观察到莫西沙星对地高辛药代动力学有临床相关影响。此外，莫西沙星不影响茶碱的药代动力学，反之亦然。这一结果，加上进一步证明与格列本脲、华法林和口服避孕药缺乏相互作用的数据，证实了如先前报道的那样，不存在涉及细胞色素P - 450系统的代谢相互作用。丙磺舒的联合给药不影响莫西沙星的消除。因此，莫西沙星具有独特的药物相互作用概况，这对其安全使用有利。
